## Guardant Health Stock Analysis## Guardant Health Stock Analysis Analyst Recommendations: * Average recommendation: “Moderate Buy” * 14 buy ratings * 1 hold rating Target Price: * Average one-year target price: $37.38 Recent Analyst Reports: * Stephens: “Overweight” rating, $44.00 price target * Craig Hallum: “Buy” rating, $28.00 price target * Canaccord Genuity Group: “Buy” rating, $38.00 price target * Goldman Sachs Group: “Buy” rating, $32.00 price target * Guggenheim: “Buy” rating, $36.00 price target Technical Analysis: * Trading 4.3% lower at $31.15 * 50-day SMA: $28.18 * 200-day SMA: $23.19 Financial Performance: * Quarterly EPS: -($0.94) (in line with estimates) * Revenue: $168.49 million (above estimates) * Net margin: -76.34% * Return on equity: -246.47% * Forward EPS estimate: -3.31 Hedge Fund Activity: * Institutional investors and hedge funds own 92.60% of the company’s stock * Notable increases in holdings from Manchester Capital Management, Headlands Technologies, Van ECK Associates, EntryPoint Capital, and Wealthcare Advisory Partners Company Profile: Guardant Health is a precision oncology company that offers blood and tissue testing, datasets, and analytics. Its products and services include Guardant360, GuardantINFINITY Assay, GuardantOMNI Assay, and GuardantINFORM, among others.
Shares of Guardant Health, Inc. (NASDAQ:GH – Get Free Report) have been given an average recommendation of “Moderate Buy” by the fifteen research firms that currently cover the stock, Marketbeat Ratings reports. One equities research analyst has rated the stock with a hold rating and fourteen have given the company a buy rating. The average one-year target price among brokerages that have updated their coverage on the stock in the last year is $37.38.
A number of research analysts have recently issued reports on GH stock. Stephens reiterated an “overweight” rating and gave a $44.00 price target on shares of Guardant Health in a research note on Friday, May 24th. Craig Hallum initiated coverage on shares of Guardant Health in a research note on Wednesday, April 24th. They set a “buy” rating and a $28.00 price target for the company. Canaccord Genuity Group increased their price target on Guardant Health from $30.00 to $38.00 and gave the company a “buy” rating in a report on Tuesday, June 4th. The Goldman Sachs Group increased their price target on Guardant Health from $28.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Guggenheim raised Guardant Health from a “neutral” rating to a “buy” rating and set a $36.00 price target on the stock in a report on Friday, June 28th.
Check out our latest stock report on Guardant Health
Guardant Health is trading 4.3% lower
Shares of NASDAQ GH opened at $31.15 on Friday. The company has a current ratio of 5.95, a quick ratio of 5.66 and a debt-to-equity ratio of 16.70. The stock has a market cap of $3.81 billion, a PE ratio of -7.95 and a beta of 1.13. Guardant Health has a 12-month low of $15.81 and a 12-month high of $41.06. The stock has a 50-day simple moving average of $28.18 and a 200-day simple moving average of $23.19.
Guardant Health (NASDAQ:GH – Get Free Report) last released its quarterly earnings results on Thursday, May 09. The company reported ($0.94) EPS for the quarter, to the consensus estimate of ($0.94). The company had revenue of $168.49 million during the quarter, compared to analyst estimates of $150.51 million. Guardant Health had a negative net margin of 76.34% and a negative return on equity of 246.47%. On average, equity analysts predict that Guardant Health will post -3.31 EPS for the current year.
Hedge funds weigh Guardant Health
Institutional investors and hedge funds have recently added to and reduced their stakes in the company. Manchester Capital Management LLC acquired a new position in shares of Guardant Health during the first quarter worth $57,000. Headlands Technologies LLC increased its holdings in Guardant Health by 362.3% during the fourth quarter. Headlands Technologies LLC now owns 2,353 shares of the company’s stock worth $64,000 after purchasing an additional 1,844 shares in the last quarter. Van ECK Associates Corp increased its position in shares of Guardant Health by 29.4% during the fourth quarter. Van ECK Associates Corp now owns 2,702 shares of the company’s stock worth $73,000 after purchasing an additional 614 shares during the period. EntryPoint Capital LLC acquired a new position in shares of Guardant Health during the first quarter worth approximately $75,000. Finally, Wealthcare Advisory Partners LLC grew its holdings in Guardant Health by 17.9% in the 4th quarter. Wealthcare Advisory Partners LLC now owns 8,596 shares of the company’s stock worth $233,000 after acquiring an additional 1,308 shares during the period. Institutional investors and hedge funds own 92.60% of the company’s stock.
Company Profile of Guardant Health
(Get Free Report
Guardant Health, Inc., a precision oncology company, offers blood and tissue testing, datasets, and analytics in the United States and internationally. The company offers Guardant360; Guardant360 LDT; Guardant360 CDx Assay; Guardant360 Response Assay; Guardant360 TissueNext Assay; GuardantINFINITY Assay; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable modifications to potentially relevant clinical trials; GuardantOMNI Assay for advanced cancers; and GuardantINFORM, an in silico research platform for tumor development and treatment resistance in multiple biomarker-driven cancers.
Also see
Get daily news and reviews for Guardant Health – Enter your email address below to receive a concise daily summary of the latest news and analyst ratings on Guardant Health and related companies with MarketBeat.com’s FREE daily email newsletter.
